The recent study from McKinsey claims 45% of world's disease burden could be addressed by biological means. With the increasing number of cancer and other rare diseases, there is no surprise that biotech innovations are on the rise. To supplement that, advancements in biotechnology such as next-generation sequencing techniques and personalized medicines have made the large-scale development of biological drugs easier and more cost-effective.
The prior art, containing patents for biological gene sequences, and the claims generally include descriptions of gene sequences as a form of protection of DNA, RNA, other nucleotides and proteins. These patents are always claimed with in relation to the sequence upon which the said drug acts. This is mostly with respect to a disease which occurs as a result of sequence mutation/or a disease which the drug is used to treat for and acts upon the sequence mentioned in the claim. So metadata associated to a sequence claimed in the patents has gained more significance than before for both research and FTO perspective.
In this webinar, we look closely at how Prior Art is contributing to Drug Discovery and how the trend over the last 5 years in Prior Art landscape has made the IP & R&D professionals change the way sequence searching is done. We also look at how AI has helped platforms like PatSnap Bio to shift the approach to sequence searching to the next level and to meet the changing patenting landscape in biological sequencing.
Senior Data Scientist